Boxford, MA, United States of America

Erbay Yigit

This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: New England Biolabs, Inc.. Active years: 2024.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Erbay Yigit: Innovator in RNA Compositions

Introduction

Erbay Yigit is a notable inventor based in Boxford, MA (US). He has made significant contributions to the field of RNA research, particularly in the area of dephosphorylated oligoribonucleotides. His work has implications for various applications in biotechnology and molecular biology.

Latest Patents

Erbay Yigit holds 1 patent for his invention titled "Compositions and analysis of dephosphorylated oligoribonucleotides." This patent relates to compositions and analysis of RNA, including both natural and synthetic RNAs. The invention includes an endoribonuclease with specific amino acid sequences and an RNA end repair enzyme, which can be derived from various species or be non-naturally occurring.

Career Highlights

Erbay Yigit is currently associated with New England Biolabs, Inc., a leading company in the life sciences sector. His work at this organization has allowed him to explore innovative solutions in RNA research and contribute to advancements in the field.

Collaborations

Throughout his career, Erbay has collaborated with notable colleagues, including Ivan R Correa, Jr. and Eric Wolf. These collaborations have fostered a productive environment for research and innovation.

Conclusion

Erbay Yigit's contributions to RNA research and his innovative patent highlight his role as a significant inventor in the biotechnology field. His work continues to influence advancements in molecular biology and related disciplines.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…